Glioblastoma eats drug programs alive. The list of companies that have tried to crack recurrent GBM and walked away with nothing is long enough to fill a textbook. Median survival after recurrence is measured in months, not years. The tumor sits behind the blood-brain barrier, laughing at most molecules that try to reach it.
So when a small company out of Oslo says they’ve got an oral pill that crosses the BBB and attacks glioblastoma through an entirely new mechanism, you’re allowed to be skeptical. But you should also be curious.
Hemispherian AS just dosed the first patients in a Phase 1/2a trial of GLIX1, a first-in-class TET2 activator. If you’re not familiar with TET2, here’s the short version. TET2 is an enzyme that helps maintain normal epigenetic regulation. Cancer cells, especially in GBM, mess with this system to protect themselves from DNA damage. GLIX1 restores TET2 activity, which forces the tumor into a kind of self-inflicted DNA crisis. The cancer cell’s own broken epigenetics become its weakness.
The Biotech Voyager
Early-stage biotech signals, personalized.
The signals that matter to you — contextualized and written directly to you — so you cut through the noise and immediately understand why it matters.
It’s oral. That alone is worth pausing on. Most oncology approaches for brain tumors involve infusions, implants, or convection-enhanced delivery. A pill that a patient takes at home and that actually gets into the brain? That changes the treatment burden equation completely.
The trial is a collaboration with BioLineRx, the Israeli biopharma company that already has an FDA-approved product (APHEXDA, a CXCR4 inhibitor for stem cell mobilization in multiple myeloma). BioLineRx has been building out a joint venture with Hemispherian around GLIX1, so there’s real infrastructure behind this, not just a biotech with a poster and a dream.
No efficacy data yet. No enrollment numbers disclosed. No endpoints shared publicly. This is as early as it gets. But the mechanism is genuinely novel, the drug is oral, it crosses the BBB in preclinical work, and it’s targeting a disease where patients are desperate for anything new. That’s enough to put it on the radar.
GBM has broken a lot of hearts in this industry. Maybe an epigenetic angle from Norway is what it takes to break through.
